Management of Anti-Diabetic Agents in Patients with Pancreatitis

Recommended Agents

Insulin is the preferred agent during acute pancreatitis as it does not stimulate pancreatic secretion and effectively manages hyperglycemia and insulin resistance 1
The American College of Clinical Nutrition recommends exogenous insulin to maintain blood glucose as close as possible to the normal range (ideally 150-200 mg/dL during acute management) 1
Insulin addresses both acute glycemic control and the underlying metabolic derangements present in pancreatitis patients, with the American Diabetes Association noting its importance in management 3
Multiple daily injection regimens are typically required, with half of daily requirements given as prandial coverage and half as once-daily long-acting insulin, as suggested by the Journal of Clinical Oncology 4

GLP-1 receptor agonists have unresolved concerns regarding increased pancreatitis risk and should be discontinued if pancreatitis is suspected, according to the American Diabetes Association 2
DPP-4 inhibitors have been linked to pancreatitis and should be discontinued if pancreatitis develops, as noted by the American Journal of Kidney Diseases 5
The American Diabetes Association recommends avoiding GLP-1 receptor agonists in patients with a history of pancreatitis due to the potential increased risk 2

Avoid lipid-containing parenteral nutrition as triglyceride values should be kept below 12 mmol/L (ideally within normal ranges) during acute pancreatitis, as recommended by Clinical Nutrition 1
Monitor blood glucose hourly until stable, then every 2-4 hours, and monitor serum calcium levels as hypocalcemia is common and associated with worse outcomes, according to the Journal of Clinical Oncology 4
Transition from insulin to oral agents only after complete resolution of pancreatitis and careful consideration of medication-related pancreatitis risk, as suggested by the American College of Clinical Nutrition 3

Never continue GLP-1 agonists or DPP-4 inhibitors in patients with active or recent pancreatitis despite their glycemic efficacy, as recommended by the American Diabetes Association 2
Do not abruptly discontinue insulin without transitioning to alternative therapy, as rebound hyperglycemia can occur, according to the Journal of Clinical Oncology 4